FRNM.US Freenome, Inc. Common stock
- Market cap
- USD 1.15B
- P/E
- -
- P/B
- 2.44x
- ROE
- -20.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is FRNM.US undervalued?
Graham numberThe Graham number of Freenome, Inc. Common stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Freenome, Inc. Common stock fundamental analysis
No fundamental analysis for Freenome, Inc. Common stock yet.
Freenome, Inc. Common stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Freenome, Inc. Common stock
Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops SimpleScreen" CRC, a blood-based test, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as …
Full company profileFreenome, Inc. Common stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Freenome, Inc. Common stock annual financial statements
| Item | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|
| Income Statement | |||
| Revenue | 2.88M | 30.4M | 253M |
| Gross Profit | 318K | -169M | 171M |
| Operating Income | -292M | -223M | -76.6M |
| EBITDA | -259M | -199M | -52.1M |
| Net Income | -274M | -219M | -96.6M |
| EPS | -2.59 | -8.28 | -0.94 |
| Balance Sheet | |||
| Total Assets | 552M | 507M | 734M |
| Total Liabilities | 1.61B | 1.77B | 252M |
| Shareholders' Equity | -1.06B | -1.26B | 481M |
| Cash & Short-term Investments | 67.1M | 217M | 430M |
| Total Debt | - | 312M | 202M |
| Cash Flow | |||
| Operating Cash Flow | -196M | -111M | -207M |
| Capital Expenditure | 60.4M | 21.1M | 37.0M |
| Free Cash Flow | -257M | -132M | -244M |
| Ratios | |||
| ROE | - | - | -20.1% |
| ROA | -49.7% | -43.3% | -13.2% |
| Net Profit Margin | -9,521.9% | -721.3% | -38.1% |
| Debt to Equity | - | - | 0.42x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Freenome, Inc. Common stock dividends
Freenome, Inc. Common stock has not paid dividends in the last 2 fiscal years.
Who owns Freenome, Inc. Common stock
- Insiders 27.26%
- Institutions 51.10%
- Public & others 21.64%
- Shares outstanding 111M
- Free float 51.4M
Top funds holding FRNM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| ARK Venture D | 2.02M | 1.88% | 0.00% | Jul 2026 |
| ARK Genomic Revolution ETF | 1.79M | 1.67% | +0.58% | Oct 2026 |
| Federated Hermes Kaufmann Small Cap A | 1.08M | 1.00% | 0.00% | Sep 2026 |
| T. Rowe Price Small-Cap Stock | 1.02M | 0.95% | -10.39% | Sep 2026 |
| T. Rowe Price Instl Small-Cap Stock | 571K | 0.53% | -7.13% | Sep 2026 |
| Federated Hermes Kaufmann R | 485K | 0.45% | 0.00% | Sep 2026 |
| abrdn Healthcare Opportunities | 402K | 0.37% | -10.20% | Sep 2026 |
| Fidelity Growth Company Fund | 397K | 0.37% | 0.00% | Aug 2026 |
| Schwab US Small-Cap ETF™ | 281K | 0.26% | +0.24% | Oct 2026 |
| abrdn World Healthcare | 255K | 0.24% | -12.47% | Sep 2026 |
| Fidelity Extended Market Index | 241K | 0.22% | 0.00% | Sep 2026 |
| Federated Hermes Intl Small-Mid Co A | 137K | 0.13% | 0.00% | Sep 2026 |
| HBM Healthcare Investments AG Ord | 113K | 0.11% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 104K | 0.10% | 0.00% | Sep 2026 |
| Lord Abbett Micro Cap Growth I | 104K | 0.10% | 0.00% | Aug 2026 |
| ARK Genomic Revolution ETF A USD Acc | 98.7K | 0.09% | 0.00% | Oct 2026 |
| T. Rowe Price New Horizons | 96.9K | 0.09% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 83.9K | 0.08% | 0.00% | Sep 2026 |
| iShares Core S&P Total US Stock Mkt ETF | 82.8K | 0.08% | +0.03% | Oct 2026 |
| Fidelity Growth Company K6 | 75.6K | 0.07% | 0.00% | Aug 2026 |
Top institutions holding FRNM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| SVRN Asset Management, LLC | 16.6K | 0.02% | 0.00% | Sep 2026 |
Freenome, Inc. Common stock company profile
- Company name
- Freenome, Inc. Common stock
- Ticker
- FRNM.US
- Exchange
- USA Stocks
- Listed since
- Jul 20, 2026
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 375
- Fiscal year end
- December
- Address
- 3300 Marina Boulevard, Brisbane, CA, United States, 94005
- Phone
- 650 446 6630
- Website
- freenome.com
About Freenome, Inc. Common stock
Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops SimpleScreen" CRC, a blood-based test, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers. The company was founded in 2014 and is headquartered in Brisbane, California.
Freenome, Inc. Common stock management
8- Mr. Aaron Elliott Ph.D.CEO & Director · born 1980
- Mr. Riley EnnisCo-Founder & Chief Product Officer · born 1994
- Mr. Linh H. LeChief Financial Officer · born 1968
- Mr. Cheng-Ho Lin M.D., MHS, Ph.D.Chief Scientific Officer · born 1979
- Mr. Thomas F. Fitzpatrick J.D.Chief Legal Officer
- Ms. Julie Tran M.B.A., MSHRChief People Officer
- Ms. Sally Howard J.D.Senior Vice President of Regulatory & Quality
- Mr. Robert GuigleyChief Commercial Officer